Viridian Therapeutics Says REVEAL-1 Study Met Primary Endpoint Of Every Four Weeks (Q4W) Proptosis Responder Rate In Thyroid Eye Disease

Benzinga Newsdesk www.benzinga.com Positive 87.2%